Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial

Siobhan Sutcliffe, Cathee Till, Charlotte A Gaydos, Frank J. Jenkins, Phyllis J. Goodman, Ashraful M. Hoque, Ann W. Hsing, Ian M. Thompson, Jonathan Mark Zenilman, William G Nelson, Angelo Michael Demarzo, Elizabeth A Platz

Research output: Contribution to journalArticle

Abstract

Purpose To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case-control study nested in the Prostate Cancer Prevention Trial (PCPT). Methods Cases were men with a confirmed diagnosis of PCa after visit 2 (n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies. Results No association was observed between CMV serostatus and PCa risk (adjusted CMV seroprevalence = 67.9 % for cases and 65.2 % for controls, odds ratio = 1.13, 95 % CI 0.89-1.45). Conclusions Considering our null findings in the context of the full CMV literature, CMV infection, as measured by serostatus, does not appear to increase PCa risk.

Original languageEnglish (US)
Pages (from-to)1511-1518
Number of pages8
JournalCancer Causes and Control
Volume23
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Cytomegalovirus
Prostatic Neoplasms
Prospective Studies
Cytomegalovirus Infections
Herpesviridae
Seroepidemiologic Studies
Case-Control Studies
Prostate
Immunoglobulin G
Odds Ratio
Biopsy
Antibodies
Serum

Keywords

  • Cytomegalovirus
  • Epidemiology
  • Infection
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. / Sutcliffe, Siobhan; Till, Cathee; Gaydos, Charlotte A; Jenkins, Frank J.; Goodman, Phyllis J.; Hoque, Ashraful M.; Hsing, Ann W.; Thompson, Ian M.; Zenilman, Jonathan Mark; Nelson, William G; Demarzo, Angelo Michael; Platz, Elizabeth A.

In: Cancer Causes and Control, Vol. 23, No. 9, 09.2012, p. 1511-1518.

Research output: Contribution to journalArticle

Sutcliffe, Siobhan ; Till, Cathee ; Gaydos, Charlotte A ; Jenkins, Frank J. ; Goodman, Phyllis J. ; Hoque, Ashraful M. ; Hsing, Ann W. ; Thompson, Ian M. ; Zenilman, Jonathan Mark ; Nelson, William G ; Demarzo, Angelo Michael ; Platz, Elizabeth A. / Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. In: Cancer Causes and Control. 2012 ; Vol. 23, No. 9. pp. 1511-1518.
@article{2280786c3c8340b883eadb059337588e,
title = "Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial",
abstract = "Purpose To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case-control study nested in the Prostate Cancer Prevention Trial (PCPT). Methods Cases were men with a confirmed diagnosis of PCa after visit 2 (n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies. Results No association was observed between CMV serostatus and PCa risk (adjusted CMV seroprevalence = 67.9 {\%} for cases and 65.2 {\%} for controls, odds ratio = 1.13, 95 {\%} CI 0.89-1.45). Conclusions Considering our null findings in the context of the full CMV literature, CMV infection, as measured by serostatus, does not appear to increase PCa risk.",
keywords = "Cytomegalovirus, Epidemiology, Infection, Prostate cancer",
author = "Siobhan Sutcliffe and Cathee Till and Gaydos, {Charlotte A} and Jenkins, {Frank J.} and Goodman, {Phyllis J.} and Hoque, {Ashraful M.} and Hsing, {Ann W.} and Thompson, {Ian M.} and Zenilman, {Jonathan Mark} and Nelson, {William G} and Demarzo, {Angelo Michael} and Platz, {Elizabeth A}",
year = "2012",
month = "9",
doi = "10.1007/s10552-012-0028-5",
language = "English (US)",
volume = "23",
pages = "1511--1518",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "9",

}

TY - JOUR

T1 - Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial

AU - Sutcliffe, Siobhan

AU - Till, Cathee

AU - Gaydos, Charlotte A

AU - Jenkins, Frank J.

AU - Goodman, Phyllis J.

AU - Hoque, Ashraful M.

AU - Hsing, Ann W.

AU - Thompson, Ian M.

AU - Zenilman, Jonathan Mark

AU - Nelson, William G

AU - Demarzo, Angelo Michael

AU - Platz, Elizabeth A

PY - 2012/9

Y1 - 2012/9

N2 - Purpose To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case-control study nested in the Prostate Cancer Prevention Trial (PCPT). Methods Cases were men with a confirmed diagnosis of PCa after visit 2 (n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies. Results No association was observed between CMV serostatus and PCa risk (adjusted CMV seroprevalence = 67.9 % for cases and 65.2 % for controls, odds ratio = 1.13, 95 % CI 0.89-1.45). Conclusions Considering our null findings in the context of the full CMV literature, CMV infection, as measured by serostatus, does not appear to increase PCa risk.

AB - Purpose To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case-control study nested in the Prostate Cancer Prevention Trial (PCPT). Methods Cases were men with a confirmed diagnosis of PCa after visit 2 (n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies. Results No association was observed between CMV serostatus and PCa risk (adjusted CMV seroprevalence = 67.9 % for cases and 65.2 % for controls, odds ratio = 1.13, 95 % CI 0.89-1.45). Conclusions Considering our null findings in the context of the full CMV literature, CMV infection, as measured by serostatus, does not appear to increase PCa risk.

KW - Cytomegalovirus

KW - Epidemiology

KW - Infection

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84864873543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864873543&partnerID=8YFLogxK

U2 - 10.1007/s10552-012-0028-5

DO - 10.1007/s10552-012-0028-5

M3 - Article

VL - 23

SP - 1511

EP - 1518

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 9

ER -